Research opens new doors to treating glaucoma

By Jan Jarvis

Dr. Zode
Gulab Zode, PhD, with Ramesh Kasetti, PhD, in the lab at UNTHSC.

Glucocorticoids are often used to reduce inflammation, reduce pain and treat many conditions such as allergies and rashes. But for some people, the very drugs that treats one condition can cause another: specifically, glaucoma.

The condition, which affects more than 64.3 million people, is the second-leading cause of irreversible blindness in the world. Still, little is known about why glucocorticoid therapy elevates intraocular pressure and raises the risk of developing this disease, said Gulab Zode, PhD, Assistant Professor in Pharmacology & Neuroscience.

“We know that when people are treated with glucocorticoids, one of the possible side effects is increased intraocular pressure,” he said. “About 30 percent to 40 percent of patients develop this and if they don’t get treated, they experience vision loss.”

In a paper recently published in the Journal of Biological Chemistry, a team of scientists led by Dr. Zode discovered how glucocorticoids elevate intraocular pressure in the eye.

“There are no treatments that target the pathology of this disease, there are only drugs that act on the symptoms,” he said, “I want to know what causes the damage so that a targeted treatment could be developed.”

For years, Dr. Zode’s research has focused on what causes damage to the trabecular meshwork, a specialized tissue in the eye that maintains normal intraocular pressure by regulating aqueous humor outflow resistance.

In this article, Dr. Zode’s lab identified that glucocorticoids increase the transforming growth factor B2, which further contributes to elevation of intraocular pressure. The study establishes a central role for transforming growth factor B2 in glucocorticoid-induced glaucoma and provides therapeutic targets for the reduction of increased intraocular pressure in the eye.

“Now that we can see how transforming growth factor B2 plays a role in intraocular pressure elevation, we can block this signaling pathway,” he said. “This opens the door to the possibility of targeted treatment.”

Recent News

Tarri Wyre
  • On Campus
|Sep 26, 2023

SaferCare Texas empowers Community Health Workers to complete HSC Mental Wellness microcredential

Tarri Wyre saw the growing need to expand her mental health education. The community health worker and ambulatory care manager for Memorial Hermann Health in Houston turned to the Mental Wellness microcredential, offered by The University of North Texas Health Science Center at Fort Worth’s SaferC...
Dr. Teresa Wagner
  • On Campus
|Sep 25, 2023

Two HSC programs to host maternal health conference centered on fourth trimester

In the U.S., more than 20% of maternal deaths during pregnancy and the first year after childbirth are because of drug use, suicide or homicide, according to a study funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. In the absence of access to mental...
Jessica Rangel
  • Our People
|Sep 25, 2023

This is Whole Health: Jessica Rangel

“Many years ago, I did a home visit on an older adult whom I had cared for numerous times in the emergency department. What I knew was that she suffered from a complicated medical situation and was not receiving optimal care with periodic emergency department visits. She always came by ambulance, ...
Ashenafi 768x768
  • Our People
|Sep 20, 2023

Dr. Ashenafi Cherkos awarded prestigious AIM-AHEAD Fellowship in Leadership

Dr. Ashenafi Cherkos, assistant professor at The University of North Texas Health Science Center at Fort Worth, has been awarded the prestigious AIM-AHEAD Fellowship in Leadership for the Fall 2023 cohort. Cherkos serves in the School of Public Health’s Department of Population and Community Healt...